[HTML][HTML] Role of NLRP3 inflammasome in diabetes and COVID-19 role of NLRP3 inflammasome in the pathogenesis and treatment of COVID-19 and diabetes NLRP3 …

J Zhang, X Ma, F Liu, D Zhang, J Ling, Z Zhu… - Frontiers in …, 2023 - frontiersin.org
2019 Coronavirus Disease (COVID-19) is a global pandemic caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). A “cytokine storm”, ie, elevated levels of …

The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies

N Zhao, B Di, L Xu - Cytokine & growth factor reviews, 2021 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), exhibits a wide spectrum of clinical presentations …

[HTML][HTML] NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity

S Amin, S Aktar, MM Rahman, MMH Chowdhury - Microbes and infection, 2022 - Elsevier
NLRP3 inflammasome is a critical immune component that plays a crucial role in mounting
innate immune responses. The deleterious effects of inflammasome activation have been …

[HTML][HTML] Targeting the NLRP3 inflammasome in severe COVID-19

TL Freeman, TH Swartz - Frontiers in immunology, 2020 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the genus
Betacoronavirus within the family Coronaviridae. It is an enveloped single-stranded positive …

[PDF][PDF] SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications

V Quagliariello, A Bonelli, A Caronna… - Eur. Rev. Med …, 2020 - europeanreview.org
NLRP3 (NOD-, LRR-and pyrin domain-containing protein 3) inflammasome has recently
become an intriguing target of several chronic and viral diseases. Here, we argue that …

[HTML][HTML] Common NLRP3 inflammasome inhibitors and Covid-19: divide and conquer

GES Batiha, AI Al-Gareeb, D Rotimi, OS Adeyemi… - Scientific African, 2022 - Elsevier
Severe SARS-CoV-2 infection causes systemic inflammation, cytokine storm, and
hypercytokinemia due to activation of the release of pro-inflammatory cytokines that have …

[HTML][HTML] Novel coronavirus-induced NLRP3 inflammasome activation: a potential drug target in the treatment of COVID-19

A Shah - Frontiers in immunology, 2020 - frontiersin.org
Novel coronaviruses (nCoVs) encode ion-channel proteins called viroporins such as protein
E, open reading frame 3a (ORF3a) and ORF8a. These viroporins, via mechanisms such as …

[HTML][HTML] Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice

J Zeng, X Xie, XL Feng, L Xu, JB Han, D Yu, QC Zou… - …, 2022 - thelancet.com
Summary Background The Coronavirus Disease 2019 (COVID-19) pandemic has been a
great threat to global public health since 2020. Although the advance on vaccine …

Targeting of the NLRP3 Inflammasome for Early COVID-19

C Marchetti, K Mould, IW Tengesdal, WJ Janssen… - bioRxiv, 2021 - biorxiv.org
Following entry and replication of Severe Acute Respiratory Syndrome-coronavirus-2 (SARS-
CoV-2) into ACE2 expressing cells, the infected cells undergo lysis releasing more virus but …

The hidden role of NLRP3 inflammasome in obesity‐related COVID‐19 exacerbations: lessons for drug repurposing

I Bertocchi, F Foglietta, D Collotta, C Eva… - British journal of …, 2020 - Wiley Online Library
COVID‐19, the illness caused by SARS‐CoV‐2, has a wide‐ranging clinical spectrum that,
in the worst‐case scenario, involves a rapid progression to severe acute respiratory …